Cellect Biotechnology (APOP) Prices IPO at $6.50/ADS

Cellect Biotechnology Ltd. (Nasdaq: APOP)(Nasdaq: APOPW) announced the pricing of its initial public offering in the United States of 1,292,308 American Depository Shares (“ADSs”) and warrants to purchase up to 969,231 ADSs. Each ADS, representing 20 ordinary shares of the Company, and each warrant to purchase ADSs (in an amount equal to 75% of the ADSs purchased) are offered at a combined price to the public of $6.50. The warrants will have a per ADS exercise price of $7.50, are exercisable immediately, and will have a term of five years.

The gross proceeds to Cellect from this offering are expected to be $8,400,000, prior to deducting underwriting discounts, commissions and other estimated offering expenses. Cellect has granted the underwriters a 45-day option to purchase up to an additional 193,846 ADSs and/or warrants to purchase 145,385 ADSs to cover over-allotments, if any.

Cellect plans to use the net proceeds from the offering to fund its ongoing development plan, including its Phase I/II single arm, open label clinical trial and for working capital and other general corporate purposes.

Cellect’s ADSs and warrants are scheduled to begin trading on the NASDAQ Capital Market on July 29, 2016, under the symbols “APOP” and “APOPW”, respectively. The offering is expected to close on or about August 3, 2016, subject to customary closing conditions.

Rodman & Renshaw, a unit of H.C. Wainwright & Co., is acting as the sole book runner and Joseph Gunnar & Co., LLC is acting as co-manager for the offering.

The Securities and Exchange Commission declared effective a registration statement on Form F-1 relating to these securities on July 28, 2016. A final prospectus relating to this offering will be filed with the SEC. The offering is being made only by means of a prospectus. Copies of the prospectus relating to the offering may be obtained by contacting H.C. Wainwright & Co., 430 Park Avenue, New York, NY 10022, email: [email protected] or Joseph Gunnar & Co, LLC, Prospectus Department, 30 Broad Street, 11th Floor, New York, NY 10004, telephone 212-440-9600, email: [email protected]. Investors may also obtain these documents at no cost by visiting the Securities and Exchange Commission’s website at http://www.sec.gov. Before you invest, you should read the prospectus and other documents the Company has filed or will file with the Securities and Exchange Commission for more complete information about the Company and the offering.

You May Also Be Interested In

• Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
• Korro Bio (KRRO) Announces $70M Placement
• Benitec Biopharma (BNTC) Announces $40M Placement at $4.80/sh